We are live on
!
Find out more
SCM
Squadron Capital Management Portfolio holdings
AUM
$322M
This Fund
S&P 500
This Quarter
Est. Return
+34.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$49.3M
(+18%)
Cap. Flow
+$3.93M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
66.2%
Holding
60
New
23
Increased
11
Reduced
7
Closed
17
Avg Time Held Equity + Options
0.7
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
0.9
quarters
Avg Time Held Equity only
0.9
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1
quarter
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$16.9M |
| 2 |
IVA
Inventiva
IVA
|
+$9.13M |
| 3 |
Enliven Therapeutics
ELVN
|
+$6.79M |
| 4 |
FBRX
Forte Biosciences
FBRX
|
+$5.34M |
| 5 |
ADAG
Adagene
ADAG
|
+$4.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KALV
KalVista Pharmaceuticals
KALV
|
+$19.8M |
| 2 |
ABVX
Abivax
ABVX
|
+$14.5M |
| 3 |
Nektar Therapeutics
NKTR
|
+$8.99M |
| 4 |
Relmada Therapeutics
RLMD
|
+$7.86M |
| 5 |
ANL
Adlai Nortye Group ADS
ANL
|
+$6.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.64% |
| 2 | Miscellaneous | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Relmada Therapeutics
RLMD
$353M
| $50.9M | 15.78% |
7,350,000
-1,124,571
| -13% | -$7.86M |
2025 Q4
2 quarters
|
|
|
2
C4 Therapeutics
CCCC
$374M
| $33.6M | 10.43% |
7,200,000
+4,950,000
| +220% | +$16.9M |
2026 Q1
1 quarter
|
|
3
Cogent Biosciences
COGT
$5.23B
| $33.5M | 10.39% |
865,000
+77,508
| +10% | +$2.71M |
2025 Q4
2 quarters
|
|
4
Kodiak Sciences
KOD
$6.16B
| $19.5M | 6.05% |
500,000
+120,000
| +32% | +$4.67M |
2025 Q4
2 quarters
|
|
5
Relay Therapeutics
RLAY
$3.87B
| $18.1M | 5.63% |
970,000
+297,500
| +44% | +$4.32M |
2026 Q1
1 quarter
|
|
6
Zentalis Pharmaceuticals
ZNTL
$242M
| $17.9M | 5.57% |
3,700,000
+69,000
| +2% | +$275K |
2026 Q1
1 quarter
|
|
7
Edgewise Therapeutics
EWTX
$4.27B
| $11.8M | 3.66% |
290,000
-60,000
| -17% | -$2.07M |
2025 Q4
2 quarters
|
|
|
MAZE
8
Maze Therapeutics
MAZE
$1.45B
| $10M | 3.1% |
335,000
+77,500
| +30% | +$2.03M |
2025 Q4
2 quarters
|
|
|
IVA
9
Inventiva
IVA
$758M
| $9.2M | 2.86% |
2,435,000
+1,900,000
| +355% | +$9.13M |
2025 Q4
2 quarters
|
|
|
ANL
10
Adlai Nortye Group ADS
ANL
$1.04B
| $8.8M | 2.73% |
764,876
-500,355
| -40% | -$6.09M |
2026 Q1
1 quarter
|
|
|
11
Enliven Therapeutics
ELVN
$3.02B
| $8.12M | 2.52% |
+160,000
| New | +$6.79M |
2026 Q2
0 quarters
|
|
12
CALL
ArriVent BioPharma
AVBP
$835M
| $6.36M | 1.97% |
183,000
+73,000
| +66% | +$2.15M |
2025 Q4
2 quarters
|
|
13
Palisade Bio
PALI
$261M
| $6.27M | 1.95% |
3,000,000
| – | – |
2025 Q4
2 quarters
|
|
|
BIOA
14
CALL
BioAge Labs
BIOA
$287M
| $6.13M | 1.9% |
+250,000
| New | +$4.52M |
2026 Q2
0 quarters
|
|
15
Inhibikase Therapeutics
IKT
$262M
| $6.09M | 1.89% |
3,000,000
-500,000
| -14% | -$895K |
2025 Q4
2 quarters
|
|
|
ADAG
16
Adagene
ADAG
$181M
| $5.25M | 1.63% |
+1,250,000
| New | +$4.7M |
2026 Q2
0 quarters
|
|
|
FBRX
17
DELISTED
Forte Biosciences
FBRX
| $4.78M | 1.48% |
+225,000
| New | +$5.34M |
2026 Q2
0 quarters
|
|
18
CALL
Rezolute
RZLT
$455M
| $4.68M | 1.45% |
+900,000
| New | +$3.34M |
2026 Q2
0 quarters
|
|
19
InflaRx
IFRX
$231M
| $4.48M | 1.39% |
+2,000,000
| New | +$3.76M |
2026 Q2
0 quarters
|
|
20
Assembly Biosciences
ASMB
$476M
| $4.4M | 1.36% |
+160,000
| New | +$4.36M |
2026 Q2
0 quarters
|
|
|
CMPS
21
CALL
Compass Pathways
CMPS
$1.61B
| $4.32M | 1.34% |
+305,000
| New | +$3.1M |
2026 Q2
0 quarters
|
|
22
ProMIS Neurosciences
PMN
$88.6M
| $4.28M | 1.33% |
324,977
| – | – |
2026 Q1
1 quarter
|
|
|
CTNM
23
Contineum Therapeutics
CTNM
$501M
| $4.26M | 1.32% |
+260,000
| New | +$3.41M |
2026 Q2
0 quarters
|
|
|
CMPS
24
Compass Pathways
CMPS
$1.61B
| $4.25M | 1.32% |
+300,000
| New | +$3.04M |
2026 Q2
0 quarters
|
|
|
DFTX
25
Definium Therapeutics
DFTX
$4.94B
| $4M | 1.24% |
+85,000
| New | +$2.1M |
2026 Q2
0 quarters
|
|
Similar funds
SST
CW
WW
NAG
JGIA
EI
KF
QFPS
Squadron Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Squadron Capital Management held 60 positions worth $322M, up 18% from $273M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Squadron Capital Management's Q2 2026 filing shows 23 new, 11 increased, 7 reduced and 17 closed positions. Its largest new stake was Enliven Therapeutics: 160,000 shares worth $8.12M. The largest sale was KalVista Pharmaceuticals, an estimated $19.8M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Miscellaneous.
- Squadron Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 160,000 shares worth $8.12M.
- Squadron Capital Management added most to C4 Therapeutics in Q2 2026, an estimated $16.9M increase.
- Squadron Capital Management's biggest Q2 2026 reduction was Relmada Therapeutics, cutting an estimated $7.86M.
- Squadron Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
- Squadron Capital Management's ten largest holdings make up 66% of its $322M portfolio in Q2 2026.
- Squadron Capital Management opened 23 new positions and closed 17 in Q2 2026.
- Squadron Capital Management's portfolio value rose 18% quarter-over-quarter to $322M.
Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.